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Abstract: The compound 6:2 chlorinated polyfluorinated ether sulfonate (F-53B), a replacement for
perfluorooctanesulfonate (PFOS) in the electroplating industry, has been widely detected in numerous
environmental matrices, human sera, and organisms. Due to regulations that limit PFOS use, F-53B
use is expected to increase. Therefore, in this study, we performed a subchronic oral toxicity study of
F-53B in Sprague Dawley (SD) rats. F-53B was administered orally once daily to male and female
rats for 28 days at doses of 5, 20, and 100 mg/kg/day. There were no toxicologically significant
changes in F-53B-treated rats, except in the thyroid gland. However, F-53B slightly reduced the serum
concentrations of thyroid hormones, including triiodothyronine and thyroxine, compared with their
concentrations in the vehicle group. F-53B also induced follicular hyperplasia and was associated with
increased thyroid hormone biosynthesis-associated protein expression. These results demonstrate
that F-53B is a strong regulator of thyroid hormones in SD rats as it disrupts thyroid function. Thus,
caution should be exercised in the industrial application of F-53B as an alternative for PFOS.
Keywords: F-53B; subchronic oral toxicity; thyroid hormone; thyroid dysfunction
1. Introduction
Perfluoroalkyl and polyfluoroalkyl substances (PFASs) are a class of synthetic organic compounds
with broad applications in industrial substances and consumer products [1]. PFASs are bioaccumulative
and persistent in the environment, and their carbon–fluorine bond confers heat and chemical stability.
These properties, particularly of long-chain substances (≥C6), observed in laboratory animal studies
are of considerable concern [2].
In particular, perfluorooctanesulfonate (PFOS), perfluorooctanoic acid (PFOA), and their salts
have attracted worldwide attention in the regulatory community [3]. PFOS has several toxic effects in
rodent studies, including hepatotoxicity, neurotoxicity, and reproductive toxicity, and disrupts thyroid
function [4–7]. Due to its toxicity and potential carcinogenicity, PFOS was added to the Stockholm
Convention on Persistent Organic Pollutants in 2009 [8]. Subsequently, studies have provided
epidemiological evidence of the human health risks of PFOS [7,9]. However, due to the lack of a
suitable replacement, one of the exceptions in the convention for the production and use of PFOS was
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for the metal-plating industry. Therefore, PFOS has continued to be used in the electroplating industry,
for food contact materials and to coat frypans [10].
Due to its similar structure to PFOS, 6:2 chlorinated polyfluorinated ether sulfonate (6:2 Cl-PFAES;
Cl-C6F12-O-CF2CF2SO3) has been used as an alternative (Figure 1). Potassium 6:2 Cl-PFAES is
the major component of the commercial goods F-53B (trade name). In China, F-53B is accepted for use
in the electroplating industry. A paper by the China Metal-Plating Association revealed an annual usage
of 30–40 tons [11,12]. F-53B has been found in Arctic wildlife (0.023–0.27 ng/g) and the rivers of Western
countries (0.01–0.38 ng/L), indicating that it may have become a global pollutant [13]. In addition, recent
research demonstrated the high prevalence of F-53B components in human biomonitoring samples
in China, and 6:2 Cl-PFESA has been detected in river water, human serum, and fish muscle [14,15].
Furthermore, in an analysis of human serum and urine samples, Cl-PFESA was the most persistent
PFAS; therefore, the toxic effects of 6:2 Cl-PFESA are expected to be large [16].
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Figure 1. Molecular structural differences between C8-PFASs. All chemicals have eight carbons. 
Differences between 6:2 Cl-PFAES and PFOS are ether residue. PFOS and 6:2 Cl-PFAES contain in 
sulfonate and PFOA includes carboxylic acid residue. 
Recently, the National Toxicology Program presented toxicity reports of long-chain PFASs 
[17,18]. The reports demonstrated that PFASs with PFOA and perfluoroalkyl carboxylates induced 
changes in the serum thyroid hormone levels and relative thyroid weight. In addition, high-dose 
PFOA-treated rats exhibited thyroid gland follicular hypertrophy [17]. PFASs with PFOS and 
perfluoroalkyl sulfonates also induced changes in serum thyroid hormone concentration [18]. F-53B, 
however, was not included in these reports. In previous studies, F-53B altered thyroid hormones in 
adult zebra fish and offspring larvae [19]. F-53B has greater agonistic activity on thyroid hormone 
transport proteins than PFOS in rat pituitary cells [20]. However, these results suggest only indirect 
evidence on thyroid hormone regulation and there is not a toxicological database on thyroid 
dysfunction in rodents. 
Despite its potential thyroid toxicity, studies on the toxic effects of F-53B are relatively limited. 
Therefore, the aims of this study were to analyze the effects of F-53B on thyroid functions and to 
initiate an in vivo toxicological database for F-53B. 
2. Materials and Methods 
2.1. Test Substance 
F-53B (CAS No.: 73606-19-6, purity ≥ 99%) was obtained from ALFA Chemistry Protheragen Inc. 
(Ronkonkoma, NY, USA). The compound was dissolved in dimethyl sulfoxide (DMSO, purity > 
99.9%, Sigma-Aldrich, St. Louis, MO, USA), to prepare a stock solution, and the working solution 
was obtained by dilution in distilled water. The final concentration of DMSO was 0.01% in both 
vehicle control and treatment groups [21]. Antibodies for thyroid-stimulating hormone receptor 
(TSHR; sc-53542) and thyroperoxidase (TPO; sc-58432) were obtained from Santa Cruz Biotechnology 
(Dallas, TX, USA). 
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Differences between 6:2 Cl-PFAES and PFOS are ether residue. PFOS and 6:2 Cl-PFAES contain in
sulfonate and PFOA includes carboxylic acid residue.
Recently, the National Toxicology Program presented toxicity reports of long-chain PFASs [17,18].
The reports demonstrated that PFASs with PFOA and perfluoroalkyl carboxylates induced changes in
the serum thyroid hormone levels and relative thyroid weight. In addition, high-dose PFOA-treated rats
exhibited thyroid gland follicular hypertrophy [17]. PFASs with PFOS and perfluoroalkyl sulfonate
also induced changes in serum thyroid hormone concentration [18]. F-53B, however, was not included
in these reports. In previous studies, F-53B altered thyroid hormones in adult zebra fish and offspring
larvae [19]. F-53B has greater agonistic activity on thyroid hormone transport proteins than PFOS in
rat pituitary cells [20]. However, these results suggest only indirect evidence on thyroid hormone
regulation and there is not a toxicological database on thyroid dysfunction in rodents.
Despite its potential thyroid toxicity, studies on the toxic effects of F-53B are relatively limited.
Therefore, the aims of this study were to analyze the effects of F-53B on thyroid functions and to initiate
an in vivo toxicological database for F-53B.
2. Materials and Methods
2.1. Test Substance
F-53B (CAS No.: 73606-19-6, purity ≥ 99%) was obtained from ALFA Chemistry Protheragen Inc.
(Ronkonkoma, NY, USA). The compound was dissolved in dimethyl sulfoxide (DMSO, purity > 99.9%,
Sigma-Aldrich, St. Louis, MO, USA), to prepare a stock solution, and the working solution was obtained
by dilution in distilled water. The final concentration of DMSO was 0.01% in both vehicle control
and treatment groups [21]. Antibodies for thyroid-stimulating hormone receptor (TSHR; sc-53542)
and thyroperoxidase (TPO; sc-58432) were obtained from Santa Cruz Biotechnology (Dallas, TX, USA).
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2.2. Experimental Design
Eight-week-old male and female specific pathogen-free Sprague Dawley rats (Crl:CD (SD); n = 7
per sex and group) were purchased from Koatech (Seoul, Korea) for use in the general toxicity
studies. The rats were acclimated for 7 days after arrival at the laboratory of the National Institute of
Food and Drug Safety Evaluation of the Ministry of Food and Drug Safety (MFDS; Osong, Korea),
then randomly divided into groups. The animals were housed at a temperature of 22 ◦C ± 3 ◦C and a
relative humidity of 50% ± 20%. The animal facility was maintained under a 12-h light/dark cycle
(from 8.00 a.m. to 8.00 p.m.) with 10–20 air ventilations per hour. The animals were allowed access to
feed (LabDiet 5002; PMI Nutrition, Richmond, VA, USA) and water (autoclaved water) ad libitum.
The 28-day repeated-dose oral toxicity study was carried out according to the “Toxicity Test Standards
for Drugs” of the Korean MFDS. F-53B (5, 20, and 100 mg/kg/day) was orally administered once daily
for 28 days. The administration (from 9.30 a.m. to 11.00 a.m.) volume for all animals was 10 mL/kg
based on the most recent individual body weight. Body weights were measured twice a week during
the treatment period, on the day of grouping, and upon necropsy. Necropsy and the administration
of male rats were performed before one day. Experimental protocols involving animals in this study
were reviewed by the Institutional Animal Care and Use Committee of the MFDS (identification code:
MFDS-19-015; date of approval: 23 January 2019).
2.3. Clinical Pathology and Hormone Measurement
Approximately 0.5 mL of whole blood was collected for hematology and 1.5 mL of blood
was collected into serum separator tubes for clinical chemistry and the analysis of serum thyroid
hormone levels. Blood samples were collected in a round robin (zigzag) manner from 9.00 a.m. to
12.30 a.m. The blood was placed in 3-mL Vacutainer® tubes (BD, Franklin Lakes, NJ, USA) containing
the anticoagulant EDTA-2K. The blood samples were coagulated by incubation at room temperature
for 30 min, and were then centrifuged for 10 min (3000 rpm) to obtain serum. The hematology
parameters—red blood cell, white blood cell, platelet, neutrophil, lymphocyte, monocyte, eosinophil,
basophil, large unstained cell, and reticulocyte counts; hemoglobin and hematocrit levels;
and mean corpuscular volume, mean corpuscular hemoglobin, and mean corpuscular hemoglobin
concentration—were measured with an automated cell counter (ADVIA 2120; Siemens, Munich,
Germany). Using a TBA-200FR NEO chemistry analyzer (Toshiba, Tokyo, Japan), we assessed
the following clinical chemistry parameters: alanine aminotransferase, aspartate aminotransferase,
alkaline phosphatase, gamma glutamyl transferase, blood urea nitrogen, creatinine, total protein,
total bilirubin, total cholesterol (TCHO), glucose, triglyceride, albumin, albumin/globulin ratio, calcium,
sodium, chloride, potassium, phosphorus, high-density lipoprotein (HDL), and low-density lipoprotein
(LDL) levels. Triiodothyronine (T3), thyroxine (T4), and thyroid-stimulating hormone (TSH) were
measured with a IMMULITE® 1000 analyzer (Siemens).
2.4. Necropsy and Measurement of Organ Weight
After necropsy, we collected the following tissues for gross observation and histological analysis:
liver, kidneys, adrenal glands, brain, heart, thyroid gland, pituitary gland, spleen, thymus, testes,
epididymis, prostate, seminal vesicle, coagulating gland, ovaries, and uterus. Necropsy body weights
along with absolute organ weights were obtained, and organ-to-body weight ratios were calculated.
Representative samples of the collected organs were fixed in 10% neutral buffered formalin, except for
the testes and epididymis, which were fixed in modified Bouin solution.
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2.5. Histological Analysis and Protein Expression
All tissues were fixed in 10% formalin overnight or modified Bouin solution, as described
above, then embedded in paraffin wax, routinely processed, and sectioned into 4-µm-thick slices.
The tissue sections were de-paraffinized and then rehydrated in a descending graded series (100%,
95%, and 70%) of ethanol. We performed antigen retrieval (Dako S1699, Agilent Technologies,
Santa Clara, CA, USA) using a pressure cooker. The sections were incubated in 3% H2O2 in PBS
for 30 min to block endogenous peroxidase activity. The sections were then washed twice with
phosphate-buffered saline (PBS) and incubated with Protein Block, Serum-Free (Dako, X0909) for
1–2 h at room temperature to minimize non-specific antibody binding. We treated the sections
with M.O.M.® reagent (BMK-2202, Vector Laboratories, Burlingame, CA, USA) for 1 h when using
mouse primary antibodies. The sections were incubated with primary antibodies overnight at 4 ◦C.
After three washes in PBS, the sections were incubated with horseradish peroxidase-conjugated
secondary antibodies (Dako K4003 and K4001, Agilent Technologies) for 15 min at room temperature.
For immunohistochemistry, we developed the antibody signal with DAB (3, 3-diaminobenzidine)
(Dako K3468, Agilent Technologies) and counter-stained with Mayer’s hematoxylin (Dako S3309,
Agilent Technologies). Five rats were analyzed in each group and DAB-positive cells were quantified
in each slide. DAB-positive cells were counted in entire thyroid and one slide per one rat was analyzed.
The scanned image was analyzed by the number of DAB-positive cells per total area using the digital
pathology software, QuPath (https://qupath.github.io/).
2.6. Statistical Analysis
The results are presented as mean ± standard deviation (s.d.). All data were analyzed using a
one-way analysis of variance followed by a post hoc Dunnett’s multiple comparison test. The statistical
analyses were performed using GraphPad Prism. Differences with a p-value < 0.05 were considered
statistically significant.
3. Results
3.1. Thyroid Hormones and Thyroid Hormone-Related Parameters
After treating the rats with 0, 5, 20, or 100 mg/kg/day of F-53B for 28 days, we measured their serum
thyroid hormone levels. Total T3 and T4 serum concentrations were significantly lower in all treated
groups, in a dose-dependent manner, than in the vehicle control group. The total T3 and T4 levels were
two-fold lower in response to F-53B treatment (Figure 2A,B). However, the TSH concentration was not
changed by F-53B administration compared with vehicle treatment in male or female rats (Figure 2C).
The thyroid hormone-associated parameters, including TCHO, HDL, and LDL levels, did not differ
among the control and treated groups (Figure 2D–F).
3.2. Body and Organ Weights
There was a moderate increase in body weight in the F-53B treatment groups at day 28 that did
not reach statistical significance (Figure 3A,B). There were no significant differences among the relative
thyroid weights of the male or female rats in all groups (Figure 3C,D).
3.3. Histopathology
After treatment with F-53B, the rats exhibited largely normal thyroid histological features after
exposure to F-53B. However, we found treatment-related follicular hyperplasia in the thyroid glands at
doses of F-53B ≥ 5 mg/kg/day (Table 1; Figure 4). In particular, we observed a higher incidence of more
severe follicular cell hyperplasia in the female high-dose F-53B group. There were no treatment-related
histopathological changes in the other tissues in any of the groups.
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Table 1. Incidences of thyroid gland follicular hyperplasia in the 28-day toxicity study of F-53B.
Organs
Groups (mg/kg/day) a
Vehicle 5 20 100
Male
Thyroid gland
Hyperplasia 0 1 3 1
Female
Thyroid gland
Hyperplasia 0 0 4 5
a Thyroid gland tissues were examined five rats in dosing group respectively.
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Figure 4. Follicular hyperplasia in the thyroid glands of female Sprague Dawley rats exposed to
0 (vehicle) (A), 5 mg/kg/day (B), 20 mg/kg/day (C), and 100 mg/kg/day (D) F-53B by oral gavage for
28 days.
3.4. Thyroid Hormone Biosynthesis-Related Protein Expression
To evaluate the mechanism of thyroid hormone regulation, we investigated the expression of
thyroid hormone biosynthesis-related proteins in the rat thyroid gland by immunohistochemistry.
TSHR expression was significantly higher in the high-dose (100 mg/kg/day) F-53B group than
Toxics 2020, 8, 54 7 of 10
in the vehicle group. The protein expression of TPO also tended to be higher after F-53B
treatment (Figure 5).
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Figure 5. Immunostaining of thyroid hormone biosynthesis-associated proteins in the thyroid
gland tissue of F-53B-treated rats. Thyroid tissues were stained with thyroid-stimulating hormone
receptor (TSHR) (A) and thyroperoxidase (TPO) (B) specific antibodies to confirm the localization
and expression of the proteins in male and female rats. The data are displayed as the mean ± s.d.
For values that differ significantly as assessed by one-way analysis of variance and Dunnett’s test:
* indicates p < 0.05 compared with the vehicle control group.
4. Discussion
Thyroid hormones play critical roles in differentiation, growth, and metabolism. Thyroid hormone
secretion and synthesis are regulated by a negative feedback system that includes the hypothalamic–
pituitary–thyroid (HPT) axis. TSH secreted by the pituitary gland is the primary regulator of thyroid
hormone release and secretion [22]. Several genes play roles in the biosynthesis of thyroid hormones,
such as thyroid stimulating hormone receptor (TSHR), thyroid peroxidase (TPO), thyroglobulin (Tg),
and sodium iodide symporter (SLC5A5), in the thyroid follicle [23–25].
In 2018, the Organization for Economic Co-operation and Development test guidelines (OECD
TG 408) were revised to add thyroid hormone measurement to improve the detection of potential
endocrine toxicity [26]. The revised guideline requires the measurement of T4, T3, and TSH serum
levels, and the weight of the thyroid gland, all of which are responsive to thyroid pathway perturbation.
Besides, serum TCHO, HDL, and LDL levels should be determined as the levels of these parameters
are directly controlled by thyroid hormone action, which reports thyroid function.
In the present study, a toxicity study was performed after 28-day repeated oral administration of
F-53B in SD rats. There were no toxicologically significant changes with regard to organ weight change
or hematological and biochemical examination. The statistically significant changes were accompanied
by parameter-associated changes in the histopathological examination or were not dose-dependent
(Supplemental Materials Tables S1–S6). However, we found that the concentrations of T3 and T4 were
significantly lower in F-53B–treated rats in the absence of TSH changes. The reason for a lack of TSH
response in the face of substantially lower thyroid hormone levels is not clear, nor is it consistent
with a disruption of the HPT axis. However, the few known studies evaluating the effects of the oral
administration of PFASs on thyroid hormone status also reported decreases in thyroid hormone levels
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without compensatory increases in TSH [27,28]. We confirmed the development of thyroid follicular
hyperplasia via the histopathological examination of F-53B-treated rats, as well as increased protein
expression of TSHR and TPO by immunohistochemistry. These results indicate a compensatory
response to the marked decrease in serum thyroid hormones, such as T3 and T4, that is consistent with
the findings of other studies [17,18].
In a previous study, PFOS reduced the circulating T3 and T4 levels, with no effect on serum TSH
in rats [18]. Another study demonstrated that PFOS increased the proliferation of thyroid follicular
cells compared the control group [29]. These findings indicate that PFOS not only has a similar
structure but also induces a similar response to F-53B in an in vivo system. Similarly, PFOA induced a
decrease in serum thyroid hormone concentration and relative thyroid weight, but PFOA induced
hyperplasia of the thyroid gland in a histological examination [17]. Indeed, data regarding some PFASs
are contradictory, and hypothyroxinemia studies have reported a sexually dimorphic response pattern
to PFASs [27–30]. Recent research has demonstrated that parental exposure resulted in F-53B transfer
as well as an increase in T4 concentration in zebrafish. The significant increase in T4 and decrease in
T3 were accompanied by altered transcriptional levels of the HPT axis [19]. Those results differ from
ours, as we observed lower thyroid hormone concentrations in F-53B-treated SD rats than in controls.
This discrepancy may arise from species-specific mechanisms of the F-53B-mediated regulation of
the HPT axis. F-53B may also function more sensitively in rat thyroid glands than in zebrafish.
5. Conclusions
We performed a 28-day subchronic oral toxicity study of F-53B (5, 20, and 100 mg/kg/day) in SD rats.
The present study demonstrated that F-53B induces thyroid dysfunction in rats, characterized by reduced
T3 and T4 levels, thyroid follicular hyperplasia, and abnormal thyroid hormone biosynthesis-related
protein expression. Further studies on the consequences of these molecular mechanisms are required to
fully determine the risks associated with the use of F-53B. Our results suggest that F-53B is a powerful
regulator of thyroid hormones in rats as it disrupts thyroid function.
Supplementary Materials: The following are available online at http://www.mdpi.com/2305-6304/8/3/54/s1,
Table S1: Hematology data for male rats in the 28-day gavage study of F-53B, Table S2: Hematology data for
female rats in the 28-day gavage study of F-53B, Table S3: Clinical biochemistry data for male rats in the 28-day
gavage study of F-53B, Table S4: Clinical biochemistry data for male rats in the 28-day gavage study of F-53B,
Table S5: Relative organ weight data for male rats in the 28-day gavage study of F-53B, Table S6: Relative organ
weight data for male rats in the 28-day gavage study of F-53B.
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